

TES Bibliography

- Alger BE. Getting High on the Endocannabinoid System. *Cerebrum Dana Forum Brain Sci.* 2013.
- Argueta DA, Ventura CM et al. A balanced approach for cannabidiol use in chronic pain. *Front Pharmacol.* 2020; April 30;11:561.
- Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. *Cell* 2009;139: 267–284.
- Bisset, Kathleen M., et al. The G protein-coupled cannabinoid-1 (CB 1) receptor of mammalian brain: inhibition by phthalate esters in vitro. *Neurochemistry International* 2011; 59.5: 706-713.
- Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. *JAMA.* 2017;318(17):1708–9.
- Bosch-Bouju, Clémentine, and Sophie Layé. Dietary Omega-6/Omega-3 and Endocannabinoids: Implications for Brain Health and Diseases. *Cannabinoids in Health and Disease.* In Tech, 2016.
- Burston JJ, Sagar DR, Shao P, Bai M, King E, et al. Cannabinoid CB2 Receptors Regulate Central Sensitization and Pain Re-sponses Associated with Osteoarthritis of the Knee Joint. *PLoS ONE* 2013;8(11): e80440
- Capano A. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. *J Postgrad Med.* 2019; Nov;132:Pages 56-61.
- Clinical Focus: Pain management - Original Research. 2020; Jan;132(1):56-61.
- Corroon J, Felice JF. The Endocannabinoid System and Its Modulation by Cannabidiol (CBD). *Altern Ther Health Med.* 2019; Jun;25(S2):6-14
- Cowman MK, Schmidt TA, Raghavan P, Stecco A. Viscoelastic Properties of Hyaluronan in Physiological Conditions. *Res.* 2015; 4():622.
- De Laurentiis A, Araujo HA, Rettori V. Role of the endocannabinoid system in the neuroendocrine responses to inflammation. *Curr Pharm Des.* 2014;20(29):4697-4706.
- Di Marzo V, Piscitelli F. The Endocannabinoid System and its modulating effects by phytocannabinoids. *Neurotherapeutics.* 2015; Oct;12(4):692-698.

- Desai MJ, Saini V, Saini S. Myofascial pain syndrome: a treatment review. *Pain Ther.* 2013 Jun; 2(1):21-36.
- Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. *N Engl J Med.* 2017;376(21):2011-2020.
- di Tomaso, Emmanuelle. Brain cannabinoids in chocolate. *Nature* 1996;382: 677-678.
- Drugs of Abuse: A Dea Resource Guide. Washington, D.C.: U.S. Dept. of Justice, Drug Enforcement Administration, 2011. Inter-net resource.
- El Sohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in Cannabis Potency over the Last Two Decades (1995-2014) - Analysis of Current Data in the United States. *Biol Psychiatry.* 2016;79(7):613-619.
- Eskander JP , Spall E, Spall A, Shah R, Kaye A. Cannabidiol (CBD) as a Treatment of Acute and Chronic Back Pain: A Case Se-ries and Literature Review May/Jun 2020;16(3):215-218.
- Fede C, Pirri C, Petrelli L, Guidolin D, Fan C, De Caro R, Stecco C. Fede C, et al. Sensitivity of the Fasciae to the Endocanna-binoid System: Production of Hyaluronan-Rich Vesicles and Potential Peripheral Effects of Cannabinoids in Fascial Tissue. *Int J Mol Sci.* 2020 Apr 22;21(8):2936
- Fede C, Albertin G, Stecco C, et al. Expression of the Endocannabinoid Receptors in Human Fascial Tissue. *Eur J Histochem.* 2016;Apr 11:60(2): 2642
- Fede C, Albertin G, Petrelli L, Sfriso MM, Biz C, De Caro R, Stecco C. Expression of the endocannabinoid receptors in human fascial tissue. *Eur J Histochem.* 2016 Jun 28; 60(2):2643.
- Fernandez-Ruiz J, Romero J et al. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? *Trends in Phar-mocological Sciences.* 2006; 28(1): 39-45.
- Garantziotis S, Savani RC. Hyaluronan biology: A complex balancing act of structure, function, location and context. *Matrix Biol.* 2019 May; 78-79(1):1-10.
- Gupta S. Why I Changed My Mind on Weed. CNN. <http://www.cnn.com/2013/08/08/health/gupta-changed- mind-marijuana/index.html>. Published 2013
- Hall W, Degenhardt L. The adverse health effects of chronic cannabis use. *Drug Test Anal.* 2014;6(1-2):39- 45.

- Harrison J VanDolah HJ, Bauer BA, Mauck KF. Clinicians' Guide to Cannabidiol and Hemp Oils Mayo Clin Proc. 2019 Sep;94(9):1840-1851.
- Hassanzadeh P, Hassanzadeh A (2012) The CB1 receptor-mediated endocannabinoid signaling and NGF: the novel targets of curcumin. *Neurochemical Research* 2012; 37: 1112–1120.
- Hill KP, Palastro MD, Johnson B, Ditre JW. Cannabis and Pain: A Clinical Review. *Cannabis Cannabinoid Res.* 2017 May 1;2(1):96-104.
- Hilderbrand RL. Hemp & Cannabidiol: What is a Medicine? *Mo Med.* 2018 Jul-Aug;115(4):306-309.
- Kogan, N. M., Mechoulam, R. Cannabinoids in health and disease. *Dialogues in Clinical Neuroscience.* 2007. 9(4), 413–430.
- Kis B, Ifrim FC, Buda V, Avram S, Pavel IZ, Antal D, Paunescu V, Dehelean CA, Ardelean F, Diaconeasa Z, Soica C, Danciu C. Cannabidiol-from Plant to Human Body: A Promising Bioactive Molecule with Multi-Target Effects in Cancer. *Int J Mol Sci.* 2019 Nov 25;20(23):5905.
- LANGEVIN, H. et al. Ultrasound evidence of altered lumbar connective tissue structure in human subjects with chronic LBP. 2009. *BMC Musculoskeletal Disorders.* 10:151-160.
- Litwiniuk M, Krejner A, Speyrer MS, Gauto AR, Grzela T. Hyaluronic Acid in Inflammation and Tissue Regeneration. *Wounds.* 2016 Mar; 28(3):78-88.
- Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. *Br J Clin Pharmacol.* 2011;72:5:735-744.
- Maccarrone M, Bab I, BÍró T, et al. Endocannabinoid signaling at the periphery: 50 years after THC. *Trends Pharmacol Sci.* 2015;36(5):277-296.
- Mackie K. Cannabinoid receptors: where they are and what they do. *J Neuroendocrinol.* 2008;20 Suppl 1:10-14.
- Maytin EV. Hyaluronan: More than just a wrinkle filler. *Glycobiology.* 2016 Jun; 26(6):553-9.
- McPartland JM, Guy GW, Di Marzo V. Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System. Romanovsky AA, ed. *PLoS ONE.* 2014;9(3):e89566

- McPartland JM, Matias I, Di Marzo V, Glass M. Evolutionary origins of the endocannabinoid system. *Gene*. 2006;370:64-74.
- McPartland JM. Expression of the Endocannabinoid System in Fibroblasts and the Myofascial Tissues. *J Bodyw Mov Ther*. 2008; April;12(2):169-182.
- Mecham, Carrillo-Salinas FJ et al. Perspectives on cannabis-based therapy of multiple sclerosis: a mini-review. *Frontiers in Cellular Neurosciences*. 2020; Feb; 14; 1-7.
- Mouhamed Y, Vishnyakov A, Qorri B, et al. Therapeutic potential of medicinal marijuana: an educational primer for health care professionals. *Drug Healthc Patient Saf*. 2018;10:45–66.
- Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. *Future Med Chem*. 2009 Oct; 1(7):1333-49.
- National Academies of Sciences, Engineering and M. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. *Natl Acad Press*. 2017.
- NIH Drug Database: Dronabinol (Marinol, Synthetic THC). <https://druginfo.nlm.nih.gov/drugportal/rn/1972-08-3>.
- Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease: successes and failures. *The FEBS Journal*. 2013; 280(9), 1918–1943.
- Pandey R, Mousawy K, Nagarkatt M, Nagarkatti P. Endocannabinoids and immune regulation. *Pharmacological Research : The Official Journal of the Italian Pharmacological Society*. 2009 60(2), 85–92.
- Pharmaceuticlas G. Sativex (delta-9- tetrahydrocannabinol and cannabidiol). <https://www.gwpharm.com/products-pipeline/sativex- delta-9-tetrahydrocannabinol-and-cannabidiol>.
- Piermarini C, Viswanath O. CBD as the New Medicine in the Pain Provider's Armamentarium .
Pain Ther. 2019; 8:157–158
- Quistad, Gary B., et al. Cannabinoid CB1 receptor as a target for chlorpyrifos oxon and other organophosphorus pesticides. *Toxicology letters* 2002;135.1: 89-93.
- Romero-Sandoval EA, Kolano AL, Alvarado-Vázquez PA. Cannabis and Cannabinoids for Chronic Pain. *Curr Rheumatol Rep*. 2017 Oct 5;19(11):67

- Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br J Pharmacol*. 2011;163(7):1344-1364.
- Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes *Cannabis Cannabinoid Res*. 2016; 1(1): 154–165
- Russo EB, Guy GW et al. Cannabis pain and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. *Chem Biodivers*. 2007 Aug;4(8):1729-1743.
- Sandkuhler J. Models and mechanisms of hyperalgesia and allodynia. *Physiol Rev* 2009; 89: 7
- Slawek D, Meenrajan SR, Alois MR, Comstock Barker P, Estores IM, Cook R.J. Medical Cannabis for the Primary Care Physician. *Prim Care Community Health*. 2019 Jan-Dec;10:21501327
- Schleip R. Fascial plasticity—A new neurobiological explanation: Part 1. *J. Bodywork Mov. Ther*. 2003;7:11–19.
- Smith S, Wagner M. Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions. *Neuro Endocrinol Letters*. 2014;35(3):198-201.
- Thors L, Burston JJ, Alter BJ, McKinney MK, Cravatt BF, et al. Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolase. *British Journal of Pharmacology*. 2010;160: 549–560.
- Turcotte C, Blanchet MR et al. The CB2 receptor and its role as a regulator of inflammation. *Cellular and Molecular Life Sciences*. 2016; 73:4449-4470.
- Überall MA. A Review of Scientific Evidence for THC: CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain. 2020 Feb 14;13:399-410.
- Urits I, Borchart M, Hasegawa M, Kochanski J, Orhurhu V, Viswanath O. An update of current cannabis-based pharmaceuticals in pain medicine. *Pain and Therapy*. 2019.
- VanDolah HJ, Bauer BA, Mauck KF. Clinicians' Guide to Cannabidiol and Hemp Oils. *Mayo Clin Proc*. 2019 Sep;94(9):1840-1851
- Vučković S, Srebro D, Vujović KS, Vučetić Č, Prostran M. Cannabinoids and Pain: New Insights From Old Molecules. *Front Pharmacol*. 2018 Nov 13;9:1259.

- Walitt B, Klose P, Fitzcharles MA, Phillips T, Häuser W. Cochrane. Cannabinoids for fibromyalgia. Database Syst Rev. 2016 Jul 18;7(7):CD011694.
- Wang J. Glial Endocannabinoid System in Pain Modulation. Int J Neurosci. 2019; Jan; 129(1):94-100
- Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain. 2003; Mar; 102(1-2):211-6.
- Watkins BA. Endocannabinoids, Exercise, Pain, and a Path to Health With Aging. Mol Aspects Med. 2018;Dec;64:68-78.
- Watson JE, Kim JS, Das A., Watson JE, et al. Emerging class of omega-3 fatty acid endocannabinoids & their derivatives. Prostaglandins Other Lipid Mediat. 2019; Aug; 143:106337.
- Wong H, Cairns BE. Cannabidiol, cannabinal and their combinations act as peripheral analgesics in a rat model of myofascial pain. Arch Oral Biol. 2019 Aug; 104():33-39.
- Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000;288: 1765–1769.
- Zügel M, Maganaris CN, Wilke J, Hodges PW. Fascial tissue research in sports medicine: from molecules to tissue adaptation, injury and diagnostics: consensus statement. Br J Sports Med. 2018 Dec; 52(23):1497.